Phase 3 Recruiting Industry
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Texas: - Site 55 — Denison, Texas
- Site 34 — El Paso, Texas
- Site 51 — Houston, Texas
- Site 7 — Houston, Texas
- Site 94 — Pearland, Texas
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Texas: - UT Southwestern Medical Center — Dallas, Texas
- Texas Oncology - San Antonio — Fredericksburg, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology-Central South — Waco, Texas
Phase 3 Recruiting Industry
This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 p…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06459180
Sites in Texas: - Texas Oncology - Central/South Texas ( Site 8010) — Austin, Texas
- Texas Oncology - DFW ( Site 8003) — Fort Worth, Texas
- Houston Methodist Hospital OB/GYN ( Site 4102) — Houston, Texas
- Texas Oncology - San Antonio ( Site 8006) — San Antonio, Texas
- Texas Oncology - Northeast Texas ( Site 8009) — Tyler, Texas
Phase 3 Recruiting Industry
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…
Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in Texas: - Research Site — Dallas, Texas
- Research Site — Fort Worth, Texas
- Research Site — Houston, Texas
- Research Site — Tyler, Texas
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- M D Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
- MD Anderson League City — League City, Texas
- MD Anderson in Sugar Land — Sugar Land, Texas
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Texas: - Texas Oncology - DFW ( Site 8005) — Fort Worth, Texas
- Texas Oncology-The Woodlands ( Site 8000) — The Woodlands, Texas
- Texas Oncology - Northeast Texas ( Site 8002) — Tyler, Texas
Phase 3 Recruiting Industry
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn ab…
Sponsor: Rakuten Medical, Inc.
NCT ID: NCT06699212
Sites in Texas: - University of Texas, MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Texas: - UT Southwestern Medical Center — Dallas, Texas
- Local Institution - 2127 — Houston, Texas
- MD Anderson Cancer Center — Houston, Texas
- Local Institution - 2146 — Kingwood, Texas
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Texas: - New Experimental Therapeutics - NEXT Oncology — Austin, Texas
- UTSW - Moody Outpatient Center - Parkland Health — Dallas, Texas
- UT Southwest Simmons Cancer Center — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Texas: - Mary Crowley Cancer Research — Dallas, Texas
- MD Anderson — Houston, Texas
- NEXT Dallas — Irving, Texas
- NEXT Oncology San Antonio — San Antonio, Texas
- START Texas — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Texas: - The University of Texas, MD Anderson Cancer Center — Houston, Texas
- UT Health Mays Cancer Center — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Texas: - Avenzo Therapeutics Recruiting Site — Dallas, Texas
- Avenzo Therapeutics Recruiting Site — Houston, Texas
- Avenzo Therapeutics Recruiting Site — San Antonio, Texas
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology - DFW — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
Phase 2 Recruiting Industry
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receiv…
Sponsor: EpicentRx, Inc.
NCT ID: NCT05966194
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Texas: - Oncology Consultants, P.A. — Houston, Texas
- The University of Texas M. D. Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Texas: - Houston Methodist Hospital — Houston, Texas
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Texas: - The University of Texas MD Anderson Cancer Center - Texas Medical Center — Houston, Texas
Phase 2 Recruiting Industry
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expr…
Sponsor: AstraZeneca
NCT ID: NCT04379596
Sites in Texas: - Research Site — Houston, Texas
Phase 2 Recruiting Industry
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain a…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06769698
Sites in Texas: - Joe Arrington Cancer Research & Treatment Center — Lubbock, Texas
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ra…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06445972
Sites in Texas: - University of Texas MD Anderson Cancer Center ( Site 8920) — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT06526819
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Texas: - Mary Crowley Cancer Research — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibi…
Sponsor: Medicenna Therapeutics, Inc.
NCT ID: NCT05086692
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Sponsor: AstraZeneca
NCT ID: NCT07115043
Sites in Texas: - Research Site — Houston, Texas
- Research Site — San Antonio, Texas
Phase 2 Recruiting Academic/Other
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05783323
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas